Total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023
Dallas, Texas (PRWEB) November 01, 2014
Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.
Epidemiologists forecast that the total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023, at a decadal growth rate of 3.9%. Specifically, Spain will have the highest growth in the total prevalent cases of IBS in the 7MM between 2013 and 2023, while Japan and Germany will have a decline in the total prevalent cases of IBS in the 7MM between 2013 and 2023.
This report provides an overview of the risk factors, comorbidities, and global trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS (diagnosed and undiagnosed) segmented by age (10–18 years, 19–34 years, 35–44 years, 45–54 years, 55–64 years, 65–74 years, 75–84 years, and ≥85 years), sex, and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U]) in these markets. For this analysis, GlobalData epidemiologists defined IBS using the International Classification of Diseases, Tenth Revision (ICD-10) code for IBS (K58). Additionally, to construct the epidemiological forecast for the total prevalent cases of IBS in the 7MM, GlobalData epidemiologists used country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria.The total prevalent cases of IBS includes men and women who may or may not have been formally diagnosed as having IBS, but have been identified as having IBS symptoms using the Rome II IBS diagnostic criteria (Thompson et al., 1999).
Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235509 .
In 2013, there were 40,777,607 total prevalent cases of IBS in the 7MM. GlobalData epidemiologists forecast that the total prevalent cases in the 7MM will increase to 42,366,389 by 2023, at an Annual Growth Rate (AGR) of 0.39%. All markets, except for Germany and Japan,will see a small increase in the number of cases at varying AGRs. Since GlobalData epidemiologists held the prevalence constant throughout the forecast period, the differences observed in growth are driven by changes in the underlying population dynamics of each market.
- The Irritable Bowel Syndrome (IBS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS segmented by sex, age (10-18 years, 19-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and =85 years), and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U] in these markets.
- The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=235509 . (This is a premium report priced at US$3995 for a single user License.)
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global IBS market.
- Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IBS therapeutics in each of the markets covered.
Major Points in Table of Content
3.1. Disease Background
3.2. Risk Factors and Comorbidities
3.3. Global Trends
3.4. Forecast Methodology
3.4.1. Sources Used
3.4.2. Sources Not Used
3.4.3. Forecast Assumptions and Methods- Total Prevalent Cases of IBS
3.4.4. Forecast Assumptions and Methods. IBS Subtype Segmentations
3.5. Epidemiological Forecast forIBS (2013-2023)
3.5.1. Total Prevalent Cases of IBS
3.5.2. Age-Specific Total Prevalent Cases of IBS
3.5.3. Sex-Specific Total Prevalent Cases of IBS
3.5.4. Age-Standardized Total Prevalence of IBS
3.5.5. Total Prevalent Cases of IBS by Clinical Subtypes
3.6.1. Epidemiological Forecast Insight
3.6.2. Limitations of the Analysis
3.6.3. Strengths of the Analysis
Browse more reports on Gastrointestinal therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/gastrointestinal-therapeutics .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.